The top UK penny stocks to watch in 2026 are:
This watchlist uses a practical UK definition: London-listed shares trading below £1 at the time of review. A low share price does not make a company cheap, and prices can move above or below the threshold without changing the underlying business.
The ten companies span online retail, biotechnology, helium, lithium, tin, critical minerals, energy storage and technology investments. They have very different operating maturity, funding needs and liquidity, so they should not be treated as one homogeneous “penny stock” trade.
None of the entries is a recommendation to buy. The purpose is to identify the evidence that could strengthen each case and the risk most likely to undermine it.
Debenhams Group, formerly known as boohoo group, is the most established operating business in this watchlist. It combines the Debenhams marketplace with fashion brands and digital retail operations, making its investment case fundamentally different from a pre-revenue explorer.
The attraction is a possible recovery in brand performance, margins and cash generation as management simplifies the group and develops the Debenhams platform. Investors should focus on active customers, gross margin, inventory, marketing efficiency, free cash flow and progress in strengthening the balance sheet.
The main risk is that a low share price can disguise a difficult turnaround. Weak consumer demand, intense online competition, returns, discounting and execution costs can prevent revenue from converting into cash. The relevant comparison is enterprise value and sustainable earnings, not the number of pence per share.
Poolbeg Pharma is a clinical-stage biopharmaceutical company developing treatments in areas including cancer-immunotherapy complications. Its value depends on clinical evidence, intellectual property and the ability to secure partnerships or funding that can move programmes through development.
Recent work around POLB 001 provides a clear set of milestones to monitor. Trial recruitment, safety, biological activity, patent coverage and discussions with potential partners can each change the probability of commercial progress.
Biotechnology outcomes remain binary. A promising mechanism may not produce sufficient clinical benefit, development can take longer than expected and additional trials can require significant capital. Investors should separate patent announcements from evidence that improves the probability of approval and commercial use.
Sareum Holdings develops small-molecule therapeutics, with SDC-1801 as its principal clinical programme. The company’s 2026 progress includes the publication of Phase 1 data, giving investors more evidence than a purely preclinical story but not eliminating the long path to commercialisation.
The next stages should be judged through safety, dosing, pharmacokinetics, biomarker evidence, trial design and the funding or partnership route for further studies. Clear peer-reviewed results can improve credibility, while a well-defined development plan helps estimate time and capital requirements.
The principal risks are clinical failure, dilution and concentration in a limited pipeline. A large percentage move in the share price may reflect the small market value and limited liquidity rather than a proportional change in long-term probability.
Helium One Global is developing helium assets in Tanzania and has also advanced the Galactica project in the United States. The company moved beyond a purely conceptual exploration story when it announced a first sale under an offtake arrangement in 2026.
Investors should monitor production consistency, realised pricing, processing performance, offtake terms and the cash required to expand. For the Tanzanian assets, appraisal, development planning and the route to commercial output remain central.
Helium markets can support attractive pricing, but small projects face geological, engineering, funding and execution risk. An offtake agreement is meaningful only when production volume, operating costs and payment terms support durable cash generation.
Kodal Minerals is focused on lithium and gold assets in West Africa, with the Bougouni lithium project providing the main development case. Its share price is highly sensitive to project milestones, ownership structure, financing and lithium-market conditions.
The most useful evidence includes construction and commissioning progress, capital spending, production guidance, recoveries, product quality and the timing of cash receipts. Investors should also understand how project economics are shared across the relevant corporate and joint-venture interests.
Lithium prices can change rapidly as supply and electric-vehicle demand expectations shift. A technically successful project can still disappoint shareholders if commissioning is delayed, costs rise or weak pricing reduces margins during the ramp-up period.
Strategic Minerals combines producing and development-stage mineral interests. The Cobre operation provides an operating reference point, while projects linked to copper and other strategic materials create additional optionality.
The attraction is the possibility that operating cash flow can support development without relying entirely on new equity. Investors should test that proposition through sales volumes, customer concentration, operating margin, cash conversion and capital commitments across the portfolio.
Small mining groups can become stretched when several assets require funding simultaneously. Commodity prices, permits, counterparties and project sequencing therefore matter as much as headline resource size.
Andrada Mining operates the Uis tin mine in Namibia and is developing a broader critical-minerals strategy that includes tin, lithium and tantalum. Unlike an early explorer, it has an operating base against which production and costs can be measured.
The central questions are whether Uis can deliver consistent output, improve recoveries and fund expansion while the company advances additional mineral opportunities. Quarterly production, unit costs, realised prices, capital expenditure and financing terms provide the clearest evidence.
Multi-commodity exposure can diversify revenue but also increases technical and capital-allocation complexity. The company remains sensitive to tin prices, operational performance and the availability of funding for growth.
CAP-XX develops and manufactures supercapacitors used where devices need rapid bursts of power, compact energy storage or support alongside batteries. The investment case depends on converting intellectual property and manufacturing capability into repeatable commercial revenue.
Orders, customer concentration, gross margin, manufacturing utilisation and operating cash flow matter more than the size of the addressable market alone. Investors should also follow product qualification cycles because design wins may take time to become material sales.
The company has a history of funding needs and a very small market value. Dilution, working-capital pressure, competition and uneven order timing can produce sharp share-price movements that are difficult to trade at the displayed quote.
Tern is an investment company focused on technology businesses, including areas connected to the Internet of Things and cybersecurity. Buying the shares provides exposure to a portfolio whose value depends on investee-company development and eventual realisations.
The most important work is a sum-of-the-parts analysis. Investors should review the latest carrying values, external funding rounds, ownership percentages, cash at the parent company and the realistic route to an exit for each material holding.
Portfolio valuations may be difficult to verify when investee companies are private. Tern can also require cash before an exit occurs, creating dilution risk at the listed-company level. A successful technical update is not equivalent to a cash realisation for shareholders.
Eurasia Mining holds mining interests associated with palladium, platinum-group metals and other resources. Its valuation has historically been influenced by potential asset transactions as well as the operating and geological value of the projects.
The company requires unusually careful assessment of ownership, licences, cash, legal conditions, sanctions exposure, transaction feasibility and the information available in audited and interim reports. Investors should distinguish binding consideration from expressions of interest or strategic discussions.
Geopolitical and execution risks are substantial. Asset sale timelines can remain uncertain, commodity values can change and limited liquidity may amplify reactions to each announcement. This makes downside planning more important than relying on a single transaction scenario.
The table shows why the same valuation method cannot be used across all ten companies. An operating retailer should be judged through margins and cash flow, while a clinical programme or mine-development project requires milestone and funding analysis.
There is no single statutory UK definition. Many investors use a share price below £1, while others focus on small market capitalisation, AIM admission or limited liquidity. The price threshold is convenient but economically incomplete.
A company with billions of shares can trade for a fraction of a penny and still have a substantial market value. Another company can consolidate its shares, lifting the price above £1 without creating any new value. Market capitalisation, enterprise value, cash, debt and the number of shares therefore matter more than the nominal price.
Very small UK shares may not be available as CFDs, and limited liquidity can make them unsuitable for leveraged trading. Bullwaves users should confirm the current instrument list in MT5 rather than assuming that every London-listed penny stock can be traded.
The platform is still useful for placing a small-company idea in market context. UK index CFDs, sector-related shares and ETF CFDs can show whether a move reflects the individual company, a commodity cycle or a broader change in risk appetite.
A lithium developer may rise because of company progress, because lithium expectations improve or because speculative resource shares rally together. Comparing the stock’s announcement with commodity-related and broader equity charts helps isolate the driver instead of attributing every move to management execution.
A penny stock can display a dramatic percentage change while offering a wide bid-offer spread and little depth. Bullwaves’ live bid and ask presentation reinforces the same discipline for available CFDs: the executable price, position size and exit conditions must be considered before a chart pattern becomes a trade.
Purchasing an underlying penny stock and trading a CFD are different exposures. A CFD does not confer shareholder ownership and may include leverage and overnight financing. The Bullwaves workflow is relevant when a liquid instrument is available and the trader has a defined short-term plan, not simply because the underlying share price is low.
The most credible UK penny-stock research begins by ignoring the small number printed beside the ticker. Debenhams Group needs a successful operating turnaround, the biotechnology companies need clinical progress, and the resource companies need technical milestones that can be financed and converted into cash.
CAP-XX and Tern require evidence that technology and portfolio value can produce sustainable shareholder returns, while Eurasia Mining carries additional transaction and geopolitical uncertainty. The watchlist is therefore a set of distinct research cases, not a ranking of guaranteed upside.
Bullwaves can support the market-analysis side of that work through charts, related shares, indices and ETF CFDs where instruments are available. The decision to hold an underlying penny stock still requires separate due diligence on ownership, filings, dilution and liquidity.
A common informal definition is a UK-listed share trading below £1. Investors may also use market capitalisation and liquidity because share price alone can be changed through splits or consolidations.
They can be difficult for beginners because prices are volatile, information may be limited and small trades can move the market. Broad funds or larger established companies generally provide simpler starting points for long-term investing.
Not necessarily. The value of the whole company depends on the share price multiplied by the number of shares, adjusted for cash and debt. A share priced at one penny can still be expensive relative to its assets or prospects.
Availability depends on the current Bullwaves instrument list and the liquidity of the underlying market. Traders should check MT5 contract specifications rather than assuming every London-listed share is offered.
The most important items are cash runway, dilution, milestone quality, liquidity and whether management converts stated plans into measurable results.
This material is general information, not investment advice or a recommendation to buy or sell any financial instrument. Investing and leveraged trading involve risk, including possible capital loss.
Navigate the trading markets and discover a world of opportunities.
Bullwaves is a trading name of Equitex Capital Limited (Registration No. 8434948-1), a company authorized and regulated by the Financial Services Authority (the "FSA", licence no. SD185) with legal registered address in CT House, office number 9A, Providence, Mahe, Seychelles and physical address in Office No. Al9C, Providence Complex, Providence, Mahe, Seychelles.
ETX Services Limited with company registration number HE455407, a company registered in Cyprus with registered address Archiepiskopou Makariou lll 160, 3026 Limassol is appointed as Independent Representative and Distributor.
Risk Disclaimer:
Over-the-counter derivatives are complex instruments and come with a high risk of losing your initial capital rapidly due to leverage. You should consider whether you understand how over-the-counter derivatives work and whether you can afford to take the high level of risk to your capital. Investing in over-the-counter derivatives carries significant risks and is not suitable for all investors.
When acquiring our derivative products you have no entitlement, right or obligation to the underlying financial asset. Equitex is not a financial advisor and all services are provided on an execution only basis. Information is of a general nature only and does not consider your financial objectives, needs or personal circumstances. Important legal documents in relation to our products and services are available on our website. You should read and understand these documents before applying for any Bullwaves products or services and obtain independent professional advice as necessary.
Regional Restrictions:
The information or services described on this website is not directed at or offered to residents of Belgium, Maldives, North Korea, United States, Afghanistan, Belarus, Central African Republic, China, Russia, Cuba, Libya, Nicaragua, Palestinian Authority/Gaza/West Bank, Venezuela and to jurisdictions on the FATF and EU/UN sanctions lists or any other person in any jurisdiction where such distribution or use would be contrary to local laws or regulations. For more information please contact our support. Clients who onboarded via www.bullwaves.com can contact our support team at support@bullwaves.com.For complaints please email us at compliance@bullwaves.com
Contact us by phone: +44 7488 822576
Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Investors should consider whether they understand how CFDs work before investing.
